Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)

NCT01247207 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG: Ataluren

Sponsor

PTC Therapeutics